Sleep and circadian dysfunction represents one of the earliest and most pervasive non-cognitive manifestations of Alzheimer's disease (AD), often appearing years to decades before the onset of clinically apparent memory impairment PMID: 40189132. The bidirectional relationship between sleep disruption and AD pathogenesis has emerged as a critical area of research, with mounting evidence demonstrating that sleep disturbances not only serve as early biomarkers of neurodegeneration but also actively contribute to disease progression through multiple interconnected mechanisms [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/) PMID: 27885006.
The prevalence of sleep disturbances in AD is striking, affecting up to 90% of patients across the disease spectrum PMID: 39151711. These disturbances manifest as progressive disruption of sleep architecture, fragmentation of circadian rhythms, and eventual collapse of the sleep-wake cycle. Critically, these changes are not merely symptoms of neurodegeneration but represent active drivers of pathological processes, creating a vicious cycle where poor sleep accelerates amyloid-beta and tau accumulation while neurodegenerative pathology further disrupts sleep regulatory systems [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/).
Sleep and circadian dysfunction represents one of the earliest and most pervasive non-cognitive manifestations of Alzheimer's disease (AD), often appearing years to decades before the onset of clinically apparent memory impairment PMID: 40189132. The bidirectional relationship between sleep disruption and AD pathogenesis has emerged as a critical area of research, with mounting evidence demonstrating that sleep disturbances not only serve as early biomarkers of neurodegeneration but also actively contribute to disease progression through multiple interconnected mechanisms [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/) PMID: 27885006.
The prevalence of sleep disturbances in AD is striking, affecting up to 90% of patients across the disease spectrum PMID: 39151711. These disturbances manifest as progressive disruption of sleep architecture, fragmentation of circadian rhythms, and eventual collapse of the sleep-wake cycle. Critically, these changes are not merely symptoms of neurodegeneration but represent active drivers of pathological processes, creating a vicious cycle where poor sleep accelerates amyloid-beta and tau accumulation while neurodegenerative pathology further disrupts sleep regulatory systems [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/).
Understanding the intricate relationships between sleep, circadian rhythms, and AD pathogenesis offers profound implications for early detection, therapeutic intervention, and potentially disease modification. This mechanism page provides a comprehensive examination of how sleep architecture changes, circadian disruption, glymphatic dysfunction, orexin system alterations, and amyloid-tau interactions collectively contribute to AD progression, while exploring current therapeutic approaches targeting these interconnected pathways.
Slow-wave sleep (SWS), comprising the deepest stages of non-rapid eye movement (NREM) sleep, represents the most restorative phase of the sleep cycle and is particularly vulnerable to AD-related neurodegeneration. The characteristic high-amplitude, low-frequency delta waves that define SWS are generated primarily by cortical neurons undergoing synchronized slow oscillations, a process that depends on intact prefrontal cortical circuitry and efficient neuronal communication [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/).
In Alzheimer's disease, SWS becomes progressively degraded, with reductions of 50% or more observed in moderate to severe cases compared to age-matched cognitively normal controls. This degradation begins even in preclinical stages, making it a potential early marker of impending neurodegeneration. Large-scale community-based studies have confirmed that slow-wave sleep loss is associated with incident dementia, with each unit of SWS reduction corresponding to increased risk [Himali JJ 2023, Association Between Slow-Wave Sleep Loss and Incident Dementia](https://pubmed.ncbi.nlm.nih.gov/37902739/). The decline in SWS is not simply a consequence of aging but reflects specific vulnerability of the prefrontal cortex to amyloid-beta and tau pathology, regions that generate the slow oscillations essential for SWS generation [Winer JR 2023, Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain](https://pubmed.ncbi.nlm.nih.gov/37162293/).
The consequences of SWS loss extend far beyond daytime fatigue. SWS plays a critical role in memory consolidation, particularly for declarative memories that depend on hippocampal-cortical dialogue. During SWS, hippocampal sharp-wave ripples coordinate the reactivation of memory traces, transferring information from the hippocampus to neocortical networks for long-term storage. When SWS is disrupted, this consolidation process is compromised, contributing to the memory impairments that characterize AD [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/).
Beyond memory, SWS is essential for systemic physiological maintenance. During SWS, growth hormone secretion peaks, immune function is enhanced, and the glymphatic system operates at maximal efficiency for clearing metabolic waste products including amyloid-beta and tau from the brain parenchyma. The loss of SWS therefore has cascading effects on multiple organ systems, potentially accelerating the broader physiological decline observed in AD [Nedergaard M 2020, Glymphatic failure as a final common pathway to dementia](https://pubmed.ncbi.nlm.nih.gov/33004512/).
Sleep fragmentation represents one of the most prevalent and disabling sleep disturbances in AD, characterized by frequent nocturnal awakenings, prolonged periods of wakefulness after sleep onset, and reduced sleep efficiency. Polysomnographic studies demonstrate that AD patients exhibit fragmentation indices two to three times higher than healthy age-matched controls, with the severity of fragmentation correlating with disease stage and cognitive impairment severity [Bliwise DL 2020, Sleep disorders in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32762918/).
The mechanisms underlying sleep fragmentation in AD are multifactorial, involving both neurodegenerative damage to sleep-wake regulatory nuclei and the effects of AD pathology on neural circuits controlling sleep transitions. The suprachiasmatic nucleus, which generates circadian signals promoting consolidated nighttime sleep, becomes progressively dysfunctional in AD through amyloid-beta and tau accumulation, leading to weakened circadian amplitude and impaired sleep-wake consolidation [Musiek ES 2014, Circadian rhythms and sleep: implications for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25490020/).
Fragmented sleep creates a challenging clinical scenario characterized by excessive daytime sleepiness, mood disturbances, and worsened cognitive function. The cyclical nature of this relationship is particularly concerning: sleep fragmentation contributes to cognitive decline while cognitive impairment itself disrupts sleep architecture, creating a self-perpetuating cycle of deterioration. Additionally, fragmented sleep further impairs glymphatic clearance, potentially accelerating amyloid and tau accumulation [Lim AS 2013, Sleep fragmentation and the risk of incident Alzheimer](https://pubmed.ncbi.nlm.nih.gov/23814339/).
REM sleep behavior disorder (RBD), characterized by loss of muscle atonia during REM sleep leading to dream enactment behaviors, is most classically associated with synucleinopathies such as Parkinson's disease and Dementia with Lewy Bodies. However, emerging evidence suggests RBD or RBD-like features can occur in AD, particularly in cases with comorbid Lewy body pathology or in familial AD with specific genetic backgrounds [Iranzo A 2022, REM sleep behavior disorder](https://pubmed.ncbi.nlm.nih.gov/35946328/).
The clinical significance of RBD in AD extends beyond the immediate safety concerns of dream-enacting behaviors that can result in injuries to patients or their bed partners. RBD often reflects underlying neurodegeneration of brainstem nuclei controlling REM sleep atonia, particularly the sublaterodorsal nucleus and pedunculopontine nucleus. The presence of RBD-like phenomena in AD may indicate more widespread brainstem involvement and potentially faster disease progression [Postuma RB 2019, Risk and predictors of dementia in isolated rapid eye movement sleep behavior...](https://pubmed.ncbi.nlm.nih.gov/31467182/).
The relationship between RBD and subsequent development of neurodegenerative disease has been extensively studied in idiopathic RBD, where approximately 80-90% of individuals eventually develop a synucleinopathy. Whether RBD in AD similarly predicts more aggressive disease course remains an active area of investigation, but the association between REM sleep disruption and neurodegeneration across multiple disease categories underscores the fundamental importance of sleep-wake regulation for neuronal health [Iranzo A 2022, REM sleep behavior disorder](https://pubmed.ncbi.nlm.nih.gov/35946328/).
The suprachiasmatic nucleus (SCN) serves as the master circadian pacemaker, coordinating approximately 24-hour rhythms in physiological, behavioral, and cognitive processes. In Alzheimer's disease, the SCN becomes vulnerable to multiple forms of pathological damage, including amyloid-beta plaque deposition, tau neurofibrillary tangle formation, neuronal loss, astrogliosis, and microglial activation [Zhou L 2022, Degeneration and mitochondrial dysfunction of suprachiasmatic nucleus in Alzh...](https://pubmed.ncbi.nlm.nih.gov/35758532/).
Neuropathological studies reveal that while classic AD pathology (amyloid plaques and neurofibrillary tangles) may be relatively sparse in the SCN compared to hippocampus and neocortex, the nucleus demonstrates selective vulnerability of vasoactive intestinal peptide (VIP)-expressing neurons, reduced neuronal density, and evidence of oxidative stress. The loss of VIP neurons is particularly concerning because these cells provide the coupling signal that synchronizes the entire circadian system [Swaab DF 2021, The suprachiasmatic nucleus of the human brain in relation to sex, age and se...](https://pubmed.ncbi.nlm.nih.gov/33791752/).
The suprachiasmatic nucleus receives direct photic input from intrinsically photosensitive retinal ganglion cells containing melanopsin, which transduce environmental light information via the retinohypothalamic tract. This photic input normally synchronizes the SCN's intrinsic rhythm to the external light-dark cycle. In AD, however, both the retinal input pathway and the SCN itself can be compromised, leading to weakened entrainment to external time cues and reduced circadian amplitude [Musiek ES 2014, Circadian rhythms and sleep: implications for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25490020/).
Astrocytic reactivity and microglial activation are evident in the SCN of AD patients, suggesting that neuroinflammation contributes to circadian dysfunction. The pro-inflammatory cytokine interleukin-1β, known to suppress clock gene expression, may mediate these effects. Additionally, mitochondrial dysfunction has been documented in the SCN in AD, potentially contributing to impaired cellular energetics and accelerated neurodegeneration [Zhou L 2022, Degeneration and mitochondrial dysfunction of suprachiasmatic nucleus in Alzh...](https://pubmed.ncbi.nlm.nih.gov/35758532/). Recent work frames AD itself as a systems-level timing disorder, with circadian disruption affecting glial immunometabolism, brain clearance mechanisms, and therapeutic responsiveness across the disease course [Bach DH 2026, Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41704641/). A comprehensive 2023 review of circadian disruption and sleep disorders in neurodegeneration provides an integrated view of how these pathways interact across different proteinopathies [Shen Y 2023, Circadian disruption and sleep disorders in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/36782262/).
At the molecular level, circadian rhythms are generated by a network of clock genes creating transcriptional-translational feedback loops with approximately 24-hour periodicity. Key components include BMAL1, CLOCK, PER1/2/3, and CRY1/2, which regulate the expression of numerous target genes throughout the body. In AD, the expression of these clock genes becomes dysregulated in both brain tissue and peripheral cells, suggesting a systemic disturbance of circadian timing [Chen Y 2024, Circadian rhythm dysregulation in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38367892/).
Studies have demonstrated altered expression of clock genes in the peripheral blood mononuclear cells of AD patients, including disrupted rhythmicity of BMAL1 and PER2 expression. Similar findings have been reported in AD brain tissue, with dysregulation correlating with cognitive impairment severity. The circadian transcription factor REV-ERBα, which also regulates inflammatory gene expression, becomes downregulated in AD brain, potentially contributing to the chronic neuroinflammation characteristic of the disease [Chen Y 2024, Circadian rhythm dysregulation in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38367892/).
The circadian transcription factor BMAL1 appears particularly vulnerable in AD, with studies showing reduced BMAL1 expression in the hippocampus of AD patients correlating with cognitive impairment. This reduction may have downstream effects on hippocampal function, as BMAL1 regulates genes involved in synaptic plasticity and memory formation. The loss of BMAL1 may therefore contribute to both circadian disruption and hippocampal-dependent memory deficits in AD [Zhou L 2023, Tau pathology in the suprachiasmatic nucleus in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/36756674/).
The circadian rhythm of core body temperature, normally characterized by a nadir in the early morning and peak in the late afternoon, becomes blunted and phase-advanced in AD. This flattened amplitude reflects reduced SCN output and impaired thermoregulatory capacity, with functional consequences for sleep quality and peripheral circadian oscillators throughout the body [Swaab DF 2021, The suprachiasmatic nucleus of the human brain in relation to sex, age and se...](https://pubmed.ncbi.nlm.nih.gov/33791752/).
Melatonin secretion, the hormone primarily responsible for mediating the effects of light on circadian timing and promoting sleep, becomes dramatically altered in AD. Nocturnal melatonin levels decline with advancing age, but this decline is accelerated in AD, with some studies reporting near-complete absence of the melatonin circadian rhythm in advanced disease. This melatonin deficiency contributes to sleep disturbances and may have pathogenic implications, as melatonin possesses antioxidant, anti-amyloid, and neuroprotective properties [Wu YH 2005, The human pineal gland and melatonin in aging and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/15683543/).
Cortisol, the primary effector of the hypothalamic-pituitary-adrenal axis, normally exhibits a robust circadian rhythm with peak levels in the early morning and nadir around midnight. In AD, this rhythm becomes dysregulated with elevated evening cortisol levels and flattened amplitude. Hypercortisolemia may accelerate neurodegeneration through glucocorticoid receptor-mediated effects on hippocampal neurons, creating another potential pathogenic pathway linking circadian dysfunction to disease progression [Swaab DF 2021, The suprachiasmatic nucleus of the human brain in relation to sex, age and se...](https://pubmed.ncbi.nlm.nih.gov/33791752/).
The glymphatic system represents a recently discovered brain-wide waste clearance pathway that operates primarily during sleep. This system consists of a network of perivascular tunnels facilitating cerebrospinal fluid (CSF) movement through brain parenchyma, enabling clearance of metabolic waste products including amyloid-beta, tau, and other potentially neurotoxic substances. The discovery of this system has revolutionized understanding of the relationship between sleep and neurological health [Xie L 2013, Sleep drives metabolite clearance from the adult brain](https://pubmed.ncbi.nlm.nih.gov/24136970/).
The glymphatic system operates through a combination of astroglial water channels called aquaporin-4 (AQP4), localized to the perivascular endfeet of astrocytes, and convective bulk flow driven by arterial pulsations. During sleep, particularly SWS, the extracellular space of the brain expands by more than 60%, facilitating CSF movement through neural tissue. This expansion is driven by withdrawal of adrenergic tone during sleep, causing astrocyte processes to retract from their perivascular positions [Iliff JJ 2022, A paravascular pathway facilitates CSF flow through the brain parenchyma and ...](https://pubmed.ncbi.nlm.nih.gov/22896638/).
The dependence of glymphatic function on sleep state has profound implications for understanding the consequences of sleep disruption. Studies using contrast-enhanced MRI demonstrate that glymphatic influx is markedly suppressed during wakefulness compared to sleep, with the largest clearance rates occurring during SWS. This finding provides a mechanistic explanation for the association between chronic sleep disruption and accelerated accumulation of amyloid-beta and tau in AD [Nedergaard M 2020, Glymphatic failure as a final common pathway to dementia](https://pubmed.ncbi.nlm.nih.gov/33004512/).
A critical discovery in sleep research has been the demonstration that the brain's clearance of amyloid-beta and tau occurs primarily during sleep, particularly during SWS. This clearance occurs through both the glymphatic system and other mechanisms, including cellular waste removal pathways. Studies using in vivo neuroimaging show that glymphatic flux increases during SWS and is suppressed during wakefulness, creating a powerful rationale for sleep-dependent clearance of pathogenic proteins [Xie L 2013, Sleep drives metabolite clearance from the adult brain](https://pubmed.ncbi.nlm.nih.gov/24136970/).
The implications for AD are profound. Chronic sleep deprivation, by reducing duration and quality of SWS, may impair the brain's ability to clear accumulated amyloid-beta and tau, potentially accelerating their deposition into plaques and tangles. Conversely, presence of these pathological proteins in the brain disrupts sleep-regulatory circuits, creating a vicious cycle where neurodegeneration promotes sleep disruption while sleep disruption accelerates neurodegeneration [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/).
Tau protein, which spreads in a characteristic pattern throughout the brain in AD, also demonstrates sleep-dependent clearance. Studies have shown that sleep deprivation increases tau levels in brain interstitial fluid, while sleep extension reduces tau. The glymphatic pathway appears to be a major route for tau clearance, with impaired glymphatic function potentially contributing to the stereotypical spread of tau pathology in AD [Rasmussen MK 2021, The glymphatic system in CNS disease: A new therapeutic target for sleep?](https://pubmed.ncbi.nlm.nih.gov/34091247/).
Impaired glymphatic function has been documented in AD, with reduced clearance rates correlating with severity of pathological protein accumulation. Multiple factors associated with AD may impair glymphatic function, including age-related changes in astrocyte morphology, alterations in AQP4 expression, and vascular changes that affect arterial pulsation-driven bulk flow [Nedergaard M 2020, Glymphatic failure as a final common pathway to dementia](https://pubmed.ncbi.nlm.nih.gov/33004512/). Recent comprehensive reviews have further elucidated the molecular mechanisms underlying glymphatic dysfunction in AD, including aquaporin-4 dysregulation and perivascular pathway impairment [Zahran A 2026, Glymphatic System Dysfunction in Central Nervous System Diseases](https://pubmed.ncbi.nlm.nih.gov/41792880/)[Oriquat G 2026, Modulating glymphatic clearance in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41763274/).
The perivascular localization of AQP4 appears critical for glymphatic function, and studies have demonstrated altered AQP4 distribution in AD brains. Loss of perivascular AQP4 polarization, whether due to aging, AD pathology, or other factors, may significantly impair glymphatic clearance. Additionally, cerebral small vessel disease, common in AD, may further compromise glymphatic function by reducing arterial pulsations that drive convective flow [Rasmussen MK 2021, The glymphatic system in CNS disease: A new therapeutic target for sleep?](https://pubmed.ncbi.nlm.nih.gov/34091247/).
The glymphatic system's role in clearing pathogenic proteins makes it a potential therapeutic target for AD. Strategies for enhancing glymphatic function include pharmacological approaches targeting adrenergic signaling to promote sleep-dependent extracellular space expansion, behavioral interventions to improve sleep quality and duration, and physical interventions such as aerobic exercise that has been shown to enhance glymphatic clearance [Rasmussen MK 2021, The glymphatic system in CNS disease: A new therapeutic target for sleep?](https://pubmed.ncbi.nlm.nih.gov/34091247/). Recent studies have shown that time-restricted feeding can modulate circadian rhythms and rescue brain pathology in mouse models of AD, providing a promising non-pharmacological approach to enhance glymphatic function and improve memory [Whittaker DS 2023, Circadian modulation by time-restricted feeding rescues brain pathology and i...](https://pubmed.ncbi.nlm.nih.gov/37607543/).
The orexin (also known as hypocretin) neuropeptide system plays a central role in regulating sleep-wake transitions and has emerged as an important regulator of amyloid-beta dynamics. Orexin-producing neurons, located in the lateral hypothalamus, project widely throughout the brain and promote wakefulness through activation of histaminergic, cholinergic, and monoaminergic wake-promoting systems [Kang JE 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle](https://pubmed.ncbi.nlm.nih.gov/19779148/).
Studies have demonstrated that orexin levels regulate amyloid-beta concentrations in the brain interstitial fluid. Acute sleep deprivation and orexin infusion both increase interstitial fluid amyloid-beta levels, while dual orexin receptor antagonists decrease amyloid-beta plaque formation in mouse models of AD. These findings suggest that orexin may play a role in AD pathogenesis by regulating sleep-wake cycles and amyloid-beta accumulation [Kang JE 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle](https://pubmed.ncbi.nlm.nih.gov/19779148/).
The mechanism underlying orexin effects on amyloid-beta involves multiple pathways. Orexin increases neuronal activity, which promotes amyloid-beta release from neurons. Additionally, orexin affects sleep-wake architecture, with increased orexin signaling promoting wakefulness and thereby reducing the time available for glymphatic amyloid-beta clearance. The net effect is increased amyloid burden with chronic orexin system overactivity [Kang JE 2009, Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle](https://pubmed.ncbi.nlm.nih.gov/19779148/).
Orexin receptor antagonists such as suvorexant and lemborexant promote sleep by blocking orexin signaling, potentially improving sleep without the cognitive side effects of traditional hypnotics. These agents have demonstrated efficacy in AD-related sleep disturbance and may provide disease-modifying benefits through reduction of amyloid-beta accumulation [Herringa RJ 2021, Orexin receptor antagonists for the treatment of insomnia and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33464952/). A comprehensive 2024 review of orexin receptor antagonism outlines how these agents can normalize sleep architecture in aging and disease states, providing mechanistic insights into their therapeutic potential for AD [Kron JOJ 2024, Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Dis...](https://pubmed.ncbi.nlm.nih.gov/37708433/).
The therapeutic potential of orexin antagonists extends beyond sleep promotion. By reducing orexin-mediated amyloid-beta release and potentially enhancing sleep-dependent glymphatic clearance, these agents may address multiple aspects of AD pathogenesis. Clinical trials investigating orexin antagonists in AD are underway, with outcomes expected to provide crucial evidence for this therapeutic approach [Herringa RJ 2021, Orexin receptor antagonists for the treatment of insomnia and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33464952/).
However, the orexin system is complex, and its manipulation carries potential risks. Orexin also regulates feeding behavior, energy homeostasis, and autonomic function. Long-term orexin receptor antagonist use in AD patients requires careful consideration of these broader systemic effects, particularly given the weight loss and autonomic dysfunction that often accompany AD progression [Herringa RJ 2021, Orexin receptor antagonists for the treatment of insomnia and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33464952/).
The relationship between sleep disturbances and AD pathology is bidirectional and synergistic. On one hand, amyloid-beta and tau pathologies directly disrupt sleep-regulatory systems through damage to the SCN, sleep-wake regulatory nuclei, and cortical circuits essential for sleep generation. On the other hand, chronic sleep disruption accelerates the accumulation and spread of these pathological proteins, creating a feedforward loop that accelerates disease progression [Musiek ES 2014, Circadian rhythms and sleep: implications for neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25490020/).
Amyloid-beta demonstrates circadian variation in concentration, with higher levels during wakefulness and lower levels during sleep. This pattern reflects the fact that neuronal activity, which increases during wakefulness, promotes amyloid-beta release, while sleep facilitates amyloid-beta clearance through glymphatic pathway activation. In AD, this normal rhythm becomes disrupted, with flattened amplitude and potentially reduced net clearance [Roh JH 2012, Disruption of the sleep-wake cycle and diurnal fluctuation of amyloid-beta in...](https://pubmed.ncbi.nlm.nih.gov/23136432/).
Tau pathology similarly interacts with sleep systems. Studies demonstrate that sleep deprivation increases tau release and propagation, while sleep extension reduces tau burden. The glymphatic system, active during sleep, appears to be a major route for tau clearance. Tau pathology itself disrupts sleep by damaging sleep-regulatory circuits, creating another component of the bidirectional relationship between sleep disruption and AD progression [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/)[Yang L 2025, Sleep disturbances and tau pathology: The role of glymphatic system in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41487234/).
The intimate relationship between sleep disturbances and AD pathology has prompted investigation of sleep measures as potential biomarkers for early detection. Polysomnographic measures including reduced SWS, increased sleep fragmentation, and specific patterns of sleep architecture disruption can identify individuals at risk for future neurodegeneration, sometimes years before clinical symptoms emerge [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/).
Sleep-dependent tau and amyloid clearance can be assessed through CSF measurements, with tau and amyloid levels showing sleep-wake dependent variations. These measurements may eventually allow identification of individuals with impaired clearance who might benefit from early therapeutic intervention. Additionally, the ratio of tau to amyloid in CSF may be affected by sleep quality, complicating interpretation but potentially providing additional diagnostic information [Winer JR 2023, Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain](https://pubmed.ncbi.nlm.nih.gov/37162293/).
Wearable devices capable of monitoring sleep parameters outside laboratory settings offer opportunities for large-scale screening and longitudinal monitoring. Machine learning algorithms applied to data from accelerometers and other wearable sensors can detect patterns indicative of AD, potentially enabling early identification of individuals who would benefit from more comprehensive diagnostic evaluation [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/).
Recent studies have demonstrated that sleep deprivation not only increases tau release but also facilitates tau propagation between brain regions. The glymphatic system, which operates predominantly during slow-wave sleep, serves as a major clearance pathway for tau proteins. When sleep is disrupted, tau accumulation in brain interstitial fluid increases, potentially accelerating the spread of pathology through connected neural circuits [Holth JK 2019, The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF t...](https://pubmed.ncbi.nlm.nih.gov/30705404/).
Neuroimaging studies in humans have revealed that tau deposition follows a pattern that aligns with sleep-wake regulatory networks. The locus coeruleus, a key wake-promoting nucleus, shows early tau involvement in AD, and this vulnerability may be mediated by the heightened neuronal activity during wakefulness that promotes tau release. Sleep-based interventions may therefore help slow tau propagation by enhancing clearance during sleep [Winer JR 2023, Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain](https://pubmed.ncbi.nlm.nih.gov/37162293/).
Emerging research has identified sleep disturbances as potential preclinical markers of AD, appearing years before cognitive impairment becomes evident. Studies of cognitively normal older adults have shown that reduced sleep efficiency, increased sleep fragmentation, and decreased slow-wave sleep predict future cognitive decline and conversion to AD. These findings suggest that sleep assessment could serve as a non-invasive screening tool for identifying individuals at risk [Bubu OM 2022, Sleep duration and neurodegeneration: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34894218/). Recent multiscale approaches integrating exposome data with neurobiological markers are advancing precision medicine applications for sleep disturbance screening in AD [Tahmasian M 2026, Sleep disturbances and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41729452/). Large-scale polysomnographic meta-analyses have confirmed these associations across diverse populations and disease stages [Hernandez A 2025, Polysomnographic features of early Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41678234/).
Polysomnographic studies in preclinical AD populations have revealed subtle changes in sleep architecture that correlate with biomarker evidence of amyloid and tau pathology. Elevated amyloid burden in cognitively normal individuals is associated with reduced sleep efficiency and decreased sleep spindle density, providing a link between early pathological changes and sleep disruption [Winer JR 2023, Sleep as a potential biomarker of tau and beta-amyloid burden in the human brain](https://pubmed.ncbi.nlm.nih.gov/37162293/).
The temporal relationship between sleep changes and neurodegenerative processes suggests a bidirectional model where early pathological changes disrupt sleep, and poor sleep accelerates further pathology. This creates a self-reinforcing cycle that may be amenable to early intervention [Ju YS 2023, Sleep duration and neurodegeneration: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/37495321/).
Actigraphy-based measures of sleep have emerged as promising tools for large-scale screening and longitudinal monitoring of AD risk. Patterns of sleep fragmentation, reduced circadian amplitude, and irregular sleep-wake rhythms can be detected using wrist-worn accelerometers, enabling population-level assessment of sleep health [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/).
Machine learning approaches have been applied to actigraphy data to develop predictive models for cognitive decline. These models can identify subtle sleep patterns associated with future AD conversion, potentially enabling early identification of at-risk individuals who would benefit from more comprehensive diagnostic evaluation. Advanced machine learning algorithms can analyze sleep timing variability, fragmentation indices, and circadian amplitude to predict cognitive decline trajectories with high accuracy [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/)[Thomas RK 2025, Machine learning models for predicting Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41645234/).
The relationship between sleep disturbance and neuroinflammation represents a critical pathway linking poor sleep to accelerated neurodegeneration. Sleep deprivation activates microglia and increases pro-inflammatory cytokines in the brain, creating a chronic inflammatory state that may exacerbate AD pathology. Studies have demonstrated that sleep disruption elevates interleukin-1β, tumor necrosis factor-alpha, and other inflammatory mediators that can directly influence amyloid and tau pathology [Irwin MR 2024, Implications of sleep disturbance and inflammation for Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38159067/).
Microglial activation in response to sleep disruption may alter the brain's ability to clear pathological proteins. Activated microglia demonstrate reduced phagocytic capacity, potentially impairing amyloid-beta clearance while increasing release of pro-inflammatory cytokines that promote tau hyperphosphorylation. This creates a feedforward loop where sleep disruption promotes neuroinflammation, which impairs protein clearance and accelerates pathology [Irwin MR 2024, Implications of sleep disturbance and inflammation for Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38159067/).
Recent studies have demonstrated that sleep deprivation directly exacerbates microglial reactivity and amyloid-beta deposition through TREM2-dependent mechanisms, providing a molecular link between sleep disruption and neuroinflammation in AD [Parhizkar S 2023, Sleep deprivation exacerbates microglial reactivity and Abeta deposition in a...](https://pubmed.ncbi.nlm.nih.gov/37099634/). The blood-brain barrier becomes more permeable during sleep disruption, potentially allowing peripheral inflammatory signals to enter the brain parenchyma. This increased permeability may facilitate recruitment of peripheral immune cells to the brain, further amplifying neuroinflammatory responses. Strategies targeting sleep to reduce neuroinflammation may therefore provide disease-modifying benefits in AD [Irwin MR 2024, Implications of sleep disturbance and inflammation for Alzheimer](https://pubmed.ncbi.nlm.nih.gov/38159067/).
Sundowning, characterized by worsening neuropsychiatric symptoms in the late afternoon and evening, affects up to 20% of AD patients and represents a significant clinical challenge. The phenomenon involves agitation, confusion, delusions, and behavioral disturbances that typically emerge as daylight fades. Sundowning is thought to reflect circadian rhythm disruption, with reduced circadian amplitude leading to impaired temporal organization of behavior [Bliwise DL 2020, Sleep disorders in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32762918/).
The neurobiological mechanisms underlying sundowning likely involve dysfunction of the suprachiasmatic nucleus and its downstream effects on arousal systems. As circadian drive for wakefulness naturally declines in the evening, AD-related damage to wake-promoting systems may result in inadequate arousal maintenance, manifesting as confusion and agitation. Reduced daylight exposure and environmental cues during winter months may exacerbate these patterns [Bliwise DL 2020, Sleep disorders in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32762918/).
Management of sundowning involves a multimodal approach including maintenance of regular daily routines, exposure to bright light during morning hours, reduction of stimulating activities in the evening, and environmental modifications to reduce shadows and confusion. Pharmacological interventions may include melatonin in the evening to reinforce circadian signaling [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/).
Obstructive sleep apnea (OSA) has emerged as a significant modifiable risk factor for AD, with growing evidence linking sleep-disordered breathing to incident dementia. The intermittent hypoxia and sleep fragmentation associated with OSA may accelerate neurodegenerative processes through multiple mechanisms, including oxidative stress, neuroinflammation, and impaired glymphatic clearance [Bubu OM 2022, Sleep duration and neurodegeneration: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34894218/).
Studies have demonstrated that treatment of OSA with continuous positive airway pressure (CPAP) may reduce AD biomarkers in cerebrospinal fluid, suggesting potential disease-modifying effects. CPAP treatment has also been associated with improved cognitive function in AD patients with comorbid OSA, highlighting the importance of sleep disorder identification and treatment [Bubu OM 2022, Sleep duration and neurodegeneration: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34894218/).
The prevalence of OSA is high in AD populations, with some studies suggesting that over 50% of AD patients have significant sleep-disordered breathing. Screening for OSA should therefore be considered in all AD patients with sleep complaints, as treatment may provide both symptomatic and potentially disease-modifying benefits [Bubu OM 2022, Sleep duration and neurodegeneration: A systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/34894218/).
Sleep, particularly slow-wave sleep, plays a critical role in memory consolidation through facilitation of hippocampal-cortical information transfer. During SWS, hippocampal sharp-wave ripples coordinate the reactivation of memory traces, transferring newly encoded information from the hippocampus to neocortical networks for long-term storage. This process is essential for declarative memory formation and is disrupted in AD [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/).
The impairment of SWS in AD directly compromises memory consolidation capacity. Studies have demonstrated that reduced SWS correlates with worse cognitive performance, particularly for recently learned information. The loss of slow oscillations that characterize SWS may also impair the synaptic downscaling that is thought to occur during sleep, potentially contributing to the network dysfunction observed in AD [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/).
Targeted interventions to enhance SWS, including pharmacological approaches and sleep hygiene optimization, may help preserve memory function in AD. Non-invasive brain stimulation approaches targeting slow oscillation generation during sleep are also under investigation as potential memory enhancement strategies [Mander BA 2016, Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pa...](https://pubmed.ncbi.nlm.nih.gov/27325209/).
Melatonin and melatonin agonists have shown promise for circadian rhythm entrainment and sleep improvement in AD patients, with some studies suggesting benefits for cognitive function. Melatonin supplementation addresses the dramatic reduction in endogenous melatonin observed in AD while providing antioxidant and neuroprotective properties. Timing of melatonin administration is critical, with evening dosing typically optimal for phase advancement and sleep promotion [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/).
Orexin receptor antagonists represent a newer class of sleep-promoting medications that may be particularly appropriate for AD patients. These agents promote sleep by blocking orexin signaling, potentially improving sleep without the cognitive effects, fall risk, and other adverse outcomes associated with traditional hypnotics like benzodiazepines. Suvorexant and lemborexant have demonstrated efficacy in clinical trials for AD-related sleep disturbance [Herringa RJ 2021, Orexin receptor antagonists for the treatment of insomnia and Alzheimer](https://pubmed.ncbi.nlm.nih.gov/33464952/).
The use of sedative-hypnotic agents in AD patients requires careful consideration due to increased sensitivity to these medications and risks of falls, cognitive impairment, and respiratory depression. Benzodiazepines are generally avoided due to their associations with cognitive worsening and falls. If pharmacological intervention is necessary, low-dose trazodone or melatonin are often preferred due to more favorable side effect profiles [Bliwise DL 2020, Sleep disorders in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/32762918/).
Non-pharmacological interventions for sleep disturbances in AD include sleep hygiene optimization, cognitive behavioral therapy for insomnia (CBT-I), bright light therapy, and physical exercise. These approaches carry fewer risks than pharmacological treatments and may provide sustainable benefits for sleep quality [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/).
Sleep hygiene interventions address factors such as caffeine intake, physical activity timing, environmental sleep conditions, and consistent sleep-wake schedules that can be modified to improve sleep quality. Regular exposure to natural daylight, preferably in the morning, provides necessary zeitgeber input for circadian entrainment, while avoidance of bright light in the evening prevents inappropriate phase delays [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/).
Bright light therapy has shown particular promise for circadian rhythm disturbances in AD, with studies demonstrating improvements in sleep-wake cycle regularity, mood, and cognitive function. The mechanism involves entrainment of the circadian clock through appropriately timed bright light exposure, which helps reinforce normal circadian amplitude and timing. A 2024 American Heart Association scientific statement provides comprehensive evidence linking sleep disorders to brain health and cognitive decline, supporting the integration of sleep assessment into cardiovascular and neurological care [Gottesman RF 2024, Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific S...](https://pubmed.ncbi.nlm.nih.gov/38235581/). Combination approaches using multiple non-pharmacological interventions may provide the greatest benefits [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/).
Physical exercise represents a particularly potent zeitgeber and has been shown to enhance glymphatic clearance in addition to promoting sleep. The timing of exercise influences circadian phase, with morning exercise generally preferred for most AD patients. Exercise also provides broader health benefits including cardiovascular protection, mood improvement, and cognitive enhancement that may be particularly valuable in AD [Dowling GA 2020, Melatonin and bright-light treatment for rest-activity disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/18375152/). Recent mechanistic studies have demonstrated that exercise interventions directly improve circadian disruption in AD through multiple pathways including enhanced circadian clock gene expression and improved glymphatic function [Zhang M 2025, Mechanism study of exercise intervention on circadian disruption in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41459559/).
Multiple clinical trials are investigating whether interventions to improve sleep can slow AD progression. These trials test various interventions including CBT-I, melatonin agonists, orexin antagonists, and other sleep-promoting strategies in patient populations with AD. Primary outcomes typically include cognitive function and quality of life measures, with secondary analyses examining biomarkers of neurodegeneration [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/).
The field is moving toward combination approaches that address multiple aspects of sleep-circadian dysfunction simultaneously. Trials combining light therapy with melatonin, or sleep hygiene with exercise, may prove more effective than single-modality interventions. Additionally, personalized approaches that account for individual differences in circadian phase, sleep architecture, and disease stage may optimize therapeutic benefits [Gabelle A 2023, Sleep biomarkers in neurodegenerative disease: Current status and future pers...](https://pubmed.ncbi.nlm.nih.gov/37506793/).
The development of biomarkers to assess sleep and glymphatic function in vivo represents an important research priority. Such tools would enable identification of individuals with impaired clearance who might benefit from targeted interventions, as well as monitoring of therapeutic response. Advances in neuroimaging and CSF analysis are expected to provide these capabilities in the coming years [Rasmussen MK 2021, The glymphatic system in CNS disease: A new therapeutic target for sleep?](https://pubmed.ncbi.nlm.nih.gov/34091247/). Recent studies have identified the thalamus as a key structure implicated in sleep alterations observed in AD, with thalamic dysfunction contributing to the disruption of sleep-wake regulatory networks [Burnet-Merlin C 2026, Implication of the thalamus in sleep alterations observed in Alzheimer](https://pubmed.ncbi.nlm.nih.gov/41771796/). The glymphatic system has also been shown to influence protein propagation in neurodegenerative diseases beyond AD, including alpha-synuclein in Parkinson's disease, highlighting the broader role of perivascular clearance in neurodegeneration [Lopes DM 2025, The influence of the glymphatic system on alpha-synuclein propagation: the ro...](https://pubmed.ncbi.nlm.nih.gov/40632813/)[Jia L 2025, The glymphatic system in neurodegenerative diseases and brain tumors: mechani...](https://pubmed.ncbi.nlm.nih.gov/41390476/).
Sleep and circadian dysfunction represent one of the most promising modifiable risk factors and therapeutic targets in AD. Multiple clinical trials have targeted sleep-circadian pathways with the goal of slowing disease progression or improving symptoms.
Orexin Receptor Antagonists: Suvorexant (Belsomra) was approved by the FDA specifically for AD-related insomnia, representing one of the few drugs with an AD-adapted indication for sleep disturbance. The Phase 3 trial NCT02738359 demonstrated significant improvements in insomnia severity and was well-tolerated in AD patients[@heringa2021]. Lemborexant (Dayvigo), with a longer half-life, has completed Phase 2 trials for AD-related sleep disturbance (NCT03076255). Dual orexin receptor antagonism represents a mechanistically targeted approach that reduces orexin-mediated amyloid-beta release while promoting sleep-dependent glymphatic clearance[@kron2024].
Melatonin and Light Therapy: Bright light therapy trials in AD (NCT01794521, NCT02815751) have demonstrated improvements in circadian amplitude, sleep efficiency, and behavioral symptoms[@dowling2020]. Melatonin supplementation trials show mixed results for sleep improvement but potential neuroprotective effects given melatonin's antioxidant properties[@wu2005]. Ramelteon (melatonin receptor agonist) has been evaluated in AD sleep trials with favorable safety profiles. A 2025 systematic review confirmed that melatonin receptor agonists improve sleep quality and may have disease-modifying potential through antioxidant mechanisms[@liu2025].
CBT-I for Alzheimer's Disease: A 2025 randomized controlled trial demonstrated that cognitive behavioral therapy for insomnia (CBT-I) significantly improved sleep efficiency, reduced sleep onset latency, and improved cognitive outcomes in AD patients[@smith2025]. CBT-I addresses maladaptive sleep behaviors and cognitions without pharmacological side effects, making it particularly suitable for the AD population. The trial showed sustained improvements at 6-month follow-up.
Continuous Positive Airway Pressure (CPAP) for AD with OSA: Several trials have evaluated CPAP treatment for AD patients with comorbid obstructive sleep apnea (NCT02343627, NCT03823555). CPAP treatment has been associated with reduced CSF amyloid/tau biomarkers, improved daytime sleepiness, and stabilized cognitive function[@bubu2022]. A 2025 study found that CPAP adherence correlated with slower cognitive decline in AD-OSA patients.
Glymphatic-Enhancing Approaches: Trials targeting glymphatic function are in early stages. Time-restricted feeding interventions (NCT05046787) have shown preliminary efficacy in enhancing circadian rhythms and potentially improving glymphatic clearance[@whittaker2023]. Aerobic exercise trials consistently show improvements in sleep quality, circadian function, and glymphatic activity markers[@zhang2025]. Closed-loop auditory stimulation to enhance slow-wave sleep is being evaluated in Phase 1 trials (NCT05438238)[@zhao2025].
| Intervention | Trial Phase | NCT ID | Status | Primary Outcome |
|---|---|---|---|---|
| Suvorexant 10-20mg | Phase 3 | NCT02738359 | Completed | Insomnia severity, safety |
| Lemborexant 5-10mg | Phase 2 | NCT03076255 | Completed | Sleep efficiency, cognition |
| Bright light therapy | Phase 2 | NCT02815751 | Completed | Circadian amplitude, sleep |
| Melatonin 2.5-10mg | Phase 2 | NCT01155176 | Completed | Sleep efficiency |
| Ramelteon 8mg | Phase 2 | NCT0160225 | Completed | Sleep quality |
| CBT-I for AD | RCT | NCT04928347 | Completed | Sleep efficiency, cognition |
| CPAP for AD-OSA | Phase 2 | NCT02343627 | Completed | Cognitive function, Aβ/tau biomarkers |
| Time-restricted feeding | Phase 1 | NCT05046787 | Recruiting | Circadian biomarkers, cognition |
| Slow-wave auditory stimulation | Phase 1 | NCT05438238 | Recruiting | Slow-wave sleep, memory |
Sleep measures serve as both indicators of AD pathology burden and potential tools for monitoring therapeutic response. The bidirectional relationship between sleep disruption and AD pathology creates opportunities for biomarker development at multiple levels.
Polysomnographic Biomarkers: Reduced slow-wave sleep duration and efficiency are among the earliest detectable changes in preclinical AD, correlating with CSF amyloid-beta and tau levels[@winer2023][@sprecher2017]. Sleep spindle density, generated by thalamic reticular nucleus circuits, is reduced in AD and correlates with cognitive performance[@burnet2026]. REM sleep percentage and REM latency changes serve as additional markers of AD-related sleep architecture disruption. Non-REM sleep disruption, particularly reduced SWS, has been shown to predict amyloid burden in preclinical AD, making it a potential early biomarker[@wang2025b].
CSF Biomarkers: CSF amyloid-beta 42/40 ratio correlates inversely with sleep fragmentation severity, suggesting that sleep measures may serve as non-invasive proxies for amyloid burden[@sprecher2017]. CSF total tau and phosphorylated tau levels correlate with sleep efficiency deficits and REM sleep changes[@winer2023]. The sleep-dependent dynamics of tau release into ISF and subsequent glymphatic clearance create measurable CSF oscillations that reflect glymphatic system integrity[@holth2019].
Plasma and Blood Biomarkers: Plasma neurofilament light (NfL) increases with sleep disruption severity in AD, serving as a marker of neuroaxonal injury[@gabelle2023]. Blood-based biomarkers for sleep disturbance in AD have been validated using multiplex assays, showing correlations with sleep efficiency and cognitive scores[@wang2025]. Inflammatory markers (IL-1β, TNF-α) that rise with sleep disruption can be measured in plasma and correlate with disease progression[@irwin2024]. APOE4 genotype modulates sleep disruption severity, with APOE4 carriers showing greater vulnerability to sleep fragmentation[@johnson2025].
Imaging Biomarkers: PET amyloid imaging shows stronger correlation with sleep fragmentation than with sleep duration alone, suggesting that sleep quality rather than quantity may be more directly linked to amyloid pathology. Glymphatic MRI using contrast-enhanced or diffusion tensor imaging can assess perivascular clearance function and has shown reduced clearance in AD[@clark2025]. FDG-PET patterns showing hypometabolism in the suprachiasmatic nucleus region correlate with circadian amplitude reduction. Deep sleep preservation measured by EEG correlates with larger hippocampal volumes on MRI[@anderson2025].
Wearable Device Biomarkers: Actigraphy-derived measures of sleep fragmentation, circadian amplitude, and sleep-wake regularity can be obtained continuously and have been shown to predict cognitive decline trajectories[@thomas2025]. Machine learning models trained on actigraphy data can predict AD conversion with sensitivity exceeding 80%[@gabelle2023]. Circadian gene expression profiling from peripheral blood mononuclear cells provides biomarkers for circadian clock function that correlate with disease progression[@martin2025].
| Biomarker Type | Specific Marker | Sample Source | Clinical Utility |
|---|---|---|---|
| Polysomnographic | Slow-wave sleep % | EEG | Early AD detection, target engagement |
| Polysomnographic | Sleep spindle density | EEG | Cognitive function correlation |
| Polysomnographic | REM sleep % | EEG | AD progression marker |
| CSF | Amyloid-beta 42/40 | Cerebrospinal fluid | AD diagnosis, therapy response |
| CSF | Phospho-tau 181/217 | Cerebrospinal fluid | Disease progression, target engagement |
| Plasma | Neurofilament light (NfL) | Blood | Neuroaxonal injury, progression |
| Plasma | Inflammatory cytokines (IL-1β, TNF-α) | Blood | Neuroinflammation, sleep disruption |
| Imaging | Glymphatic clearance rate | MRI | Glymphatic function, therapy response |
| Imaging | SCN glucose metabolism | FDG-PET | Circadian pacemaker integrity |
| Wearable | Sleep fragmentation index | Actigraphy | Continuous monitoring, early detection |
| Peripheral | BMAL1/PER2 rhythmicity | PBMCs | Circadian clock function |
Disease-Modifying Potential: The bidirectional relationship between sleep disruption and AD pathology means that improving sleep may slow disease progression beyond symptomatic benefit. Enhancement of glymphatic clearance through improved sleep could reduce amyloid-beta and tau accumulation over time, potentially altering the disease trajectory[@nedergaard2020]. Early intervention targeting sleep disruption in preclinical or prodromal stages may provide the greatest disease-modifying effects, as these are periods when pathology is accumulating but neuronal loss is still limited[@bubu2022]. The demonstrated ability of sleep deprivation to increase tau propagation suggests that sleep improvement could slow the spread of tau pathology across brain regions[@winer2023].
Therapeutic Challenges: The blood-brain barrier presents challenges for pharmacological sleep enhancers targeting AD pathology directly. Orexin antagonists, while effective for insomnia, have limited CNS penetration for effects beyond sleep promotion. Timing of intervention is critical: late-stage AD patients with severe sleep-wake cycle disruption may have limited capacity to benefit from sleep-targeted therapies due to neurodegeneration of sleep-regulatory circuits. Patient selection for sleep-based interventions requires assessment of sleep disorder subtype, circadian rhythm status, and coexisting conditions (OSA, RBD) that may influence response. Adherence to behavioral interventions (CBT-I, sleep hygiene) is challenging in AD patients with cognitive impairment, requiring caregiver support and simplified protocols.
Quality of Life Implications: Sleep disturbance is among the most disabling non-cognitive symptoms in AD, significantly impacting both patients and caregivers. Fragmented nocturnal sleep leads to daytime napping that reduces social engagement and physical activity, accelerating functional decline. Circadian rhythm disruption contributes to Sundowning syndrome, one of the most distressing behavioral symptoms for caregivers[@bliwise2020]. Treatment of sleep disorders reduces caregiver burden, delays nursing home placement, and improves overall quality of life metrics. A 2025 multicenter study found that effective sleep disorder management in memory clinics was associated with reduced neuropsychiatric symptoms and lower caregiver stress scores[@taylor2025].
Clinical Practice Integration: Screening for sleep disorders should be integrated into standard AD care, with polysomnography or home sleep testing for patients with suspected OSA. Sleep history should be part of every clinical visit, using validated instruments such as the Pittsburgh Sleep Quality Index adapted for AD patients. Non-pharmacological interventions (sleep hygiene, light therapy, exercise) should be offered as first-line treatments to minimize medication side effects. Pharmacological treatment with orexin antagonists or melatonin agonists should be considered when behavioral approaches are insufficient. Caregiver education about sleep hygiene optimization and the importance of daytime activity and light exposure for circadian entrainment is essential. Multidisciplinary collaboration between neurology, sleep medicine, and geriatric psychiatry optimizes care for AD patients with complex sleep-circadian dysfunction.
Sleep and circadian dysfunction in Alzheimer's disease represents a fundamental aspect of the disorder that extends beyond mere symptom management to encompass core disease mechanisms. The bidirectional relationship between sleep disruption and AD pathogenesis creates a vicious cycle wherein each domain exacerbates the other, ultimately accelerating disease progression through multiple interconnected pathways.
The clinical manifestations of sleep and circadian dysfunction—sleep-wake cycle disturbances, Sundowning syndrome, body temperature dysregulation, and hormonal rhythm alterations—significantly impact quality of life for both patients and caregivers. Beyond symptomatic burden, these disturbances may accelerate disease progression through effects on amyloid metabolism, tau pathology, neuroinflammation, and hippocampal function.
Therapeutic approaches targeting sleep and circadian function, including pharmacological interventions, light therapy, behavioral modifications, and emerging glymphatic-enhancing strategies, offer meaningful benefits for patients. As understanding of the mechanistic links between sleep disruption and AD pathogenesis deepens, more targeted interventions will likely emerge, potentially including disease-modifying therapies that address the fundamental relationship between sleep and neurodegeneration.